Drug Search Results

Cemdomespib

Alternative Names: Cemdomespib, RTA-901, RTA 901, RTA901, KU-596, KU596, KU 596
Latest Update: 2025-03-25
Latest Update Note: Clinical Trial Update

Product Description

Cemdomespib is the lead product candidate from Reata's Hsp90 modulator program. Cemdomespib is a highly potent and selective, oral, small molecule C-terminal modulator of Hsp90. (Sourced from: https://www.reatapharma.com/our-science/our-technologies/hsp90-modulators/default.aspx)

Mechanisms of Action: HSP90 Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cemdomespib

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Neuralgia|Neuropathic Pain

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
CYPRESS	P2	Recruiting	Neuralgia\|Neuropathic Pain	2026-08-01

Recent News Events

Date	Type	Title
09/21/2023	News Article	Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
07/28/2023	News Article	Biogen to Acquire Reata Pharmaceuticals
06/27/2023	News Article	Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich's Ataxia
06/15/2023	News Article	Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement
01/20/2023	PubMed	Pharmacologic Targeting of the C-Terminus of Heat Shock Protein 90 Improves Neuromuscular Function in Animal Models of Charcot Marie Tooth X1 Disease.
01/15/2023	PubMed	Recent advances toward the development of Hsp90 C-terminal inhibitors.
09/15/2022	PubMed	Synthesis and evaluation of 3'- and 4'-substituted cyclohexyl noviomimetics that modulate mitochondrial respiration.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions